1Wartofsky L. Increasing world incidence of thyroid cancer: incre- ased detection or higher radiation exposure ? [J]. Hormones (Athens), 2010, 9(2): 103-108. 被引量：1
2Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcar- cinoma: a population-level analysis of 310 patients [ J ]. Cancer, 2012, 118(3): 620-627. 被引量：1
3Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer [J]. Oncologist, 2008, 13(5): 539-547. 被引量：1
4Schulten H J, AI-Maghrabi J, A1-Ghamdi K, et al. Mutational screening ofRET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNBI in medullary thyroid carcinoma [J]. Anticancer Res, 2011, 31(12): 4179-4183. 被引量：1
5de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors[J]. Endocr Rev, 2006, 27(5): 535-560. 被引量：1
6Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study [J]. J Clin Endocrinol Metab, 2008, 93(3): 682-687. 被引量：1
7Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A- RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway [J]. J Biol Chem, 2000, 275(5): 3568-3576. 被引量：1
8Sherman SI. Advances in chemotherapy of differentiated epithe- lial and medullary thyroid cancers [J]. J Clin Endocrinol Metab, 2009, 94(5): 1493-1499. 被引量：1
9Guleng B, Tateishi K, Ohta M, et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor- independent manner [J]. Cancer Res, 2005, 65(13): 5864- 5871. 被引量：1
10Gild ML, Bullock M, Robinson BG, et aL Multikinase inhibi- tors: a new option for the treatment of thyroid cancer ~ J ]. Nat Rev Endocrinol, 2011, 7(10): 617-624. 被引量：1
